Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy
Authors:
- Yuan-Yuan QuYQYuan-Yuan Qu
- Yun-Yi KongYKYun-Yi Kong
- Ding-Wei YeDYDing-Wei Ye
- Xu-Dong YaoXYXu-Dong Yao
- Shi-Lin ZhangSZShi-Lin Zhang
- Hai-Liang ZhangHZHai-Liang Zhang
- Wei-Yi YangWYWei-Yi Yang
Open Access
- 27 May 2013
- journal article
- clinical trial
- Published by Medknow in Asian Journal of Andrology
- Vol. 15 (4) , 466-470
Abstract
Androgen deprivation therapy (ADT) is a standard treatment for metastatic, recurrent and locally advanced prostate cancer (PCa). The aim of this study is to investigate the timing and extent of testosterone recovery in clinically localized PCa patients treated with radical prostatectomy (RP) and subsequent short-term adjuvant ADT. A total of 95 localized PCa patients underwent RP and 9-month adjuvant ADT were included in this prospective study. Serum testosterone level was measured before adjuvant ADT, at ADT cessation, and at 1, 3, 6, 9 and 12 months after cessation of ADT. A Cox proportional hazards model was used to assess variables associated with the time of testosterone normalization. The results showed that median patient age was 67 years and median testosterone level before adjuvant ADT was 361 (230-905) ng dl(-1). All patients finished 9-month adjuvant ADT and achieved castrate testosterone level. At 3 months after ADT cessation, testosterone recovered to supracastrate level in 97.9% patients and to normal level in 36.9% patients. The percentage of patients who recovered to normal testosterone level increased to 66.3%, 86.3% and 92.6% at 6, 9 and 12 months, respectively. Cox regression model found that higher baseline testosterone level (≥ 300 ng dl(-1)) was the only variable associated with a shorter time to testosterone normalization (hazard ratio: 1.98; P = 0.012). In conclusion, in most patients, testosterone recovered to supracastrate level at 3 months and to normal level at 12 months after 9-month adjuvant ADT cessation. Patients with higher baseline testosterone level need shorter time of testosterone normalization.Keywords
This publication has 22 references indexed in Scilit:
- Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockadeBJU International, 2012
- Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyThe Lancet Oncology, 2006
- Testosterone and erectile function recovery after radiotherapy and long‐term androgen deprivation with luteinizing hormone‐releasing hormone agonistsBJU International, 2006
- Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancerBJU International, 2006
- Time course of serum testosterone and luteinizing hormone levels after cessation of long‐term luteinizing hormone‐releasing hormone agonist treatment in patients with prostate cancerThe Prostate, 2005
- A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPYJournal of Urology, 2005
- Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinomaCancer, 2002
- Hypogonadism following prostate-bed radiation therapy for prostate carcinomaCancer, 2001
- Serum testosterone levels after external beam radiation for clinically localized prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- The Effects of External Beam Radiotherapy on Endocrine Function in Patients with Carcinoma of the ProstateJournal of Urology, 1986